Table 5.
Univariate Analysis of Prognostic Indicators of Survival and Response
| Indicator | Analyses |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Survival |
Response |
|||||||||
| Survival Type Evaluated | Hazard Ratio | 95% CI | P | Indicator Category | CR/PR |
MR/SD/PD |
P | |||
| No. | % | No. | % | |||||||
| Chromogranin A | EFS | 1.9 | 0.4 to 8.4 | .383 | Normal | 2 | 40.0 | 3 | 60.0 | .2 |
| OS | 2.1 | 0.3 to 17 | .471 | Elevated | 6 | 16.2 | 31 | 83.8 | ||
| SDHB mutation | EFS | 0.5 | 0.2 to 1.9 | .336 | Normal | 0 | 0.0 | 12 | 100.0 | .01* |
| OS | 2.0 | 0.2 to 20.7 | .558 | Mutation | 5 | 41.7 | 7 | 58.3 | ||
| Secretory | EFS | 2.4 | 0.8 to 7 | .123 | Nonsecretory | 3 | 27.3 | 8 | 72.7 | .66 |
| OS | 2.0 | 0.4 to 9.4 | .362 | Secretory | 8 | 21.1 | 30 | 78.9 | ||
| Bone and soft tissue | EFS | 1.4 | 0.6 to 3.3 | .454 | One site involved | 5 | 25.0 | 15 | 75.0 | .72 |
| OS | 0.4 | 0.1 to 1.4 | .179 | Both involved | 6 | 20.7 | 23 | 79.3 | ||
| Age, years | EFS | 1.9 | 0.9 to 4.4 | .115 | < 40 | 5 | 23.8 | 16 | 76.2 | .84 |
| OS | 2.7 | 0.8 to 9.2 | .106 | ≥ 40 | 6 | 21.4 | 22 | 78.6 | ||
| Sex | EFS | 0.9 | 0.4 to 1.9 | .696 | F | 4 | 20.0 | 16 | 80.0 | .73 |
| OS | 0.4 | 0.1 to 1.2 | .112† | M | 7 | 24.1 | 22 | 75.9 | ||
| Prior chemotherapy | EFS | 1.9 | 0.9 to 4.3 | .113 | No | 9 | 26.5 | 25 | 73.5 | .31 |
| OS | 3.4 | 1.1 to 10.3 | .031* | Yes | 2 | 13.3 | 13 | 86.7 | ||
| Prior radiation | EFS | 2.9 | 1.2 to 7.1 | .017* | No | 10 | 30.3 | 23 | 69.7 | .06 |
| OS | 2.2 | 0.7 to 6.9 | .166 | Yes | 1 | 6.3 | 15 | 93.8 | ||
| Diagnosis | EFS | 1.9 | 0.8 to 4.8 | .172 | PHEO | 4 | 26.7 | 11 | 73.3 | .64 |
| OS | 2.8 | 0.6 to 12.6 | .188 | PGL | 7 | 20.6 | 27 | 79.4 | ||
NOTE. Increased hazard ratio represents worse survival in patients who are positive for the trait. For the purposes of this analysis, patients with the following conditions were considered to be positive for the trait: elevated chromogranin A, mutated SDHB, secretory tumors, disease present in bone and soft tissue, age ≥ 40 years; male sex, prior chemotherapy or radiation therapy; diagnosis of paraganglioma.
Abbreviations: CR, complete response; PR, partial response; MR, minor response; SD, stable disease; PD, progressive disease; EFS, event-free survival; OS, overall survival; SDHB, succinate dehydrogenase subunit B; PHEO, pheochromocytoma; PGL, paraganglioma.
Significant in univariate analysis.
Significant in multivariate analysis that included sex, prior chemotherapy, prior radiation, and bone or soft tissue involvement.